Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Epidemiological and clinical studies over the past decade have firmly established that
elevated plasma concentrations of lipoprotein (a)(Lp (a)) are an important, independent and …

Background: Lipoprotein (a)[Lp (a)] may play a causal role in atherosclerosis. PCSK9
(proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce …

Over the last 10 years, there have been advances on several aspects of lipoprotein (a)
which are reviewed in the present article. Since the standard immunoassays for measuring …

There is compelling evidence that the elevated plasma lipoprotein (a)[Lp (a)] levels increase
the risk of atherosclerotic cardiovascular disease (ASCVD) in the general population. Like …

Aims Subjects with lipoprotein (a)[Lp (a)] elevation have increased arterial wall inflammation
and cardiovascular risk. In patients at increased cardiovascular risk, arterial wall …

Abstract Lipoprotein (a)(Lp (a)) is a strange lipoprotein species causatively independently
and significantly associated with cardiovascular diseases and calcified aortic valve stenosis …

Summary Lipoprotein (a)[Lp (a)] is an apolipoprotein B (apoB)-containing plasma lipoprotein
similar in structure to low-density lipoprotein (LDL). Lp (a) is more complex than LDL due to …

The high occurrence of atherosclerotic cardiovascular disease (ASCVD) events is still a
major public health issue. Although a major determinant of ASCVD event reduction is the …

Abstract Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) has revolutionized our
understanding of cholesterol homeostasis and added to our arsenal against atherosclerotic …